Skip to main content

Table 3 Prednisolone tapering regimen

From: Efficacy and safety of secukinumab in patients with giant cell arteritis: study protocol for a randomized, parallel group, double-blind, placebo-controlled phase II trial

 

60–40 mg/day at baseline

40–25 mg/day at baseline

Week

Dose mg/day

Dose mg/day

0

60–40

40–25

1

55–35

35–22

2

50–30

30–21

3

45–28

27–20

4

35–25

25–19

5

30–22

22–18

6

25–21

20–17

7

20

16

8

15

9

13

10

12

11

10

12

9

13

8

14

7

15

6

16

6

17

5

18

5

19

4

20

4

21

3

22

3

23

2

24

2

25

1

26

1

27

0

28

0